BrainsGate

Minimally Invasive Treatment for Central Nervous System Diseases

Health Tech & Life Sciences
Non Active, Aug 2026 ceased to operate

Company Overview

Snapshot

Founded in July 2000, BrainsGate operates with 11–50 employees. The company has raised $98.5M across 6 funding rounds from 11 investors. In December 2020, BrainsGate secured an F Round of funding, with BNP Paribas participating as a lead investor.

Business overview

BrainsGate is a medical device company focused on developing therapies for central nervous system diseases, particularly acute ischemic stroke. The company's core technology involves electrical stimulation of the sphenopalatine ganglion to increase cerebral blood flow. BrainsGate has developed the Ischemic Stroke System (ISS), a minimally invasive device implanted in the mouth. It serves the healthcare industry, targeting patients and healthcare providers with its medical technologies and treatments.

Strategic signal

In December 2021, BrainsGate faced a negative FDA panel outcome, attributed in part to low U.S. enrollment in its clinical trials. This event signals significant regulatory and market access challenges for the company's acute ischemic stroke treatment, indicating a potential hurdle in its commercialization pathway and future growth trajectory.

Company Intelligence Q&A

What is BrainsGate's primary focus?
BrainsGate specializes in developing minimally invasive treatments for central nervous system diseases, with a particular emphasis on acute ischemic stroke.
What was the outcome of the FDA panel review in December 2021?
In December 2021, BrainsGate received a negative FDA panel outcome, which was partly attributed to low U.S. enrollment in its clinical trials.
When did BrainsGate complete its ImPACT-1 pilot clinical trial?
BrainsGate completed its ImPACT-1 pilot clinical trial for acute ischemic stroke in 2008, which showed promising results.
Which investors participated in the December 2020 funding round?
In December 2020, BNP Paribas led a funding round for BrainsGate, with Elron Ventures also participating.
What is the Ischemic Stroke System (ISS)?
The Ischemic Stroke System (ISS) is a device developed by BrainsGate that involves implanting a miniature electrode in the roof of the mouth through a minimally invasive procedure to treat acute ischemic stroke.

External links